West Orange, N.J.-based RWJBarnabas Health recorded an operating income of $385.8 million (6.4% operating margin) in the first half of 2026, up from an operating income of $334.3 million (6.3% margin) during the same period last year, according to its financial report for the six months ended June 30.
Total operating revenue was $6.1 billion through the second quarter of 2026, up from $5.3 billion during the same period in 2025. Total patient service revenue was $5.7 billion, up from $4.9 billion. Inpatient service revenue was $2.9 billion, up from $2.4 billion, driven largely by growth in the Medicaid County Option Program — a state initiative that lets participating New Jersey counties collect a fee on hospitals to draw down added federal Medicaid match, which is then passed back to hospitals as higher reimbursement — as well as strong transplant volumes. Outpatient service revenue was $1.9 billion, up from $1.7 billion. Professional billing revenue was $791.2 million, up from $681.1 million.
Total operating expenses were $5.7 billion in the first half of 2026, up from $5 billion the prior year. Salaries and employee benefits totaled $2.6 billion, up from $2.3 billion, driven by higher labor costs tied to additional full-time employees and annual merit increases. Supplies and other expenses were $2.1 billion, up from $1.8 billion, driven in part by the opening of the Jack and Sheryl Morris Cancer Center in 2025 and higher drug costs.
RWJBarnabas reported a net income of $754.4 million in the first half of 2026, up from $607.5 million during the same period last year.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
